Sam Brusco, Associate Editor06.06.23
Illumina has elected two independent board members to join its board immediately.
Stephen MacMillan, chairman, president, and CEO of Hologic, will become and independent director and non-executive chair of Illumina’s board. Scott Ullem, corporate VP and CFO of Edwards Lifesciences will be an independent director and a member of the audit committee.
"Both Steve and Scott collectively bring more than 30 years of experience in healthcare, and the appointments are part of our continual process to attract strong independent directors. We believe these two extremely talented business executives will help broaden the skills of the current Board, especially in the fields of corporate finance and international expansion, while bringing their expertise to foster adoption of transformative medical advances across the global marketplace," Dr. Robert Epstein, Chair of the Nominating/Corporate Governance Committee, told the press. "We welcome Steve and Scott to the board and look forward to working with them to drive profitable growth and shareholder value creation."
"Steve and Scott are highly respected business leaders whose public company experience and financial acumen will be very valuable to shareholders, customers and employees," said Francis deSouza, CEO of Illumina.
Scott Ullem has been corporate VP and CFO of Edwards Lifesciences since January 2014. Before Edwards he was CFO of Bemis Company, and prior to that spent 17 years in investment banking, serving as managing director at Goldman Sachs and later Bank of America.
Stephen MacMillan, chairman, president, and CEO of Hologic, will become and independent director and non-executive chair of Illumina’s board. Scott Ullem, corporate VP and CFO of Edwards Lifesciences will be an independent director and a member of the audit committee.
"Both Steve and Scott collectively bring more than 30 years of experience in healthcare, and the appointments are part of our continual process to attract strong independent directors. We believe these two extremely talented business executives will help broaden the skills of the current Board, especially in the fields of corporate finance and international expansion, while bringing their expertise to foster adoption of transformative medical advances across the global marketplace," Dr. Robert Epstein, Chair of the Nominating/Corporate Governance Committee, told the press. "We welcome Steve and Scott to the board and look forward to working with them to drive profitable growth and shareholder value creation."
"Steve and Scott are highly respected business leaders whose public company experience and financial acumen will be very valuable to shareholders, customers and employees," said Francis deSouza, CEO of Illumina.
Independent Director Biographies
Steve MacMillan joined Hologic in December 2013 as president and CEO, and was elected chairman of the board in June 2015. From 2005 to 2012, MacMillan was president and CEO of Stryker, where he’d been president since 2003. Before 2003, he was a senior executive at Pharmacia, and he spent 11 years at Johnson & Johnson both in the U.S. and Europe. He began his career with Procter & Gamble.Scott Ullem has been corporate VP and CFO of Edwards Lifesciences since January 2014. Before Edwards he was CFO of Bemis Company, and prior to that spent 17 years in investment banking, serving as managing director at Goldman Sachs and later Bank of America.